Table 2.
The distribution of prognostic factors in 1-year LR control and LR failure subgroups in experimental and validation cohorts.
| Experimental cohort |
Validation cohort |
|||||
|---|---|---|---|---|---|---|
| 1-year LR control | 1-year LR failure | P value | 1-year LR control | 1-year LR failure | P value | |
| Age, year | ||||||
| Mean ± SD | 55.04 ± 9.15 | 51.00 ± 9.56 | 0.054 | 51.77 ± 8.62 | 51.58 ± 9.25 | 0.953 |
| Smoking, n (%) | ||||||
| No | 13 (31.7) | 11 (26.8) | 0.809 | 8 (50) | 5 (50) | 1.000 |
| Yes | 28 (68.3) | 30 (73.2) | 8 (50) | 5 (50) | ||
| cT, n (%) | ||||||
| T1-T3 | 21 (51.2) | 9 (22.0) | 0.011 | 11 (68.8) | 4 (40) | 0.228 |
| T4 | 20 (48.8) | 32 (78.0) | 5 (31.2) | 6 (60) | ||
| cN, n (%) | ||||||
| N0-N1 | 9 (22.0) | 4 (9.8) | 0.226 | 13 (81.2) | 3 (30) | 0.015 |
| N2-N3 | 32 (78.0) | 37 (90.2) | 3 (18.8) | 7 (70) | ||
| TNM, n (%) | ||||||
| Stage I-III | 9 (22.0) | 4 (9.8) | 0.226 | 9 (56.3) | 3 (30) | 0.226 |
| Stage IV | 32 (78.0) | 37 (90.2) | 7 (43.8) | 7 (70) | ||
| HG, n (%) | ||||||
| Grade 1–2 | 38 (92.7) | 39 (95.1) | 1.000 | 15 (93.8) | 10 (100) | 1.00 |
| Grade 3 | 3 (7.3) | 2 (4.9) | 1 (6.2) | 0 (0) | ||
| TV, mean ± SD, RS | 25.59 ± 24.68 | 47.73 ± 32.30 | 0.001 | 22.93 ± 29.47 | 56.40 ± 46.56 | 0.015 |
| mean ± SD | −0.36 ± 0.66 | 0.34 ± 0.54 | <0.001 | −0.46 ± 0.69 | 0.36 ± 0.94 | 0.006 |
Abbreviations: LR, loco-regional; n, number; cT, clinical T stage; cN, clinical N stage; TNM, clinical TNM stage; HG, histologic grade; IC, induction chemotherapy; TV, Tumor volume; SD, standard deviation; Q1, first quartile; Q3, third quartile.